Michael Millward

Abstract A005: D3S-002: A Purposefully Designed ERK1/2 Inhibitor Achieving Low-Dose, Pulsatile Target Inhibition for Combination with D3S-001, a New-Generation KRAS G12C Inhibitor

Jing Zhang, Wenqian Wang, Zhiqiang Zheng, Xin Xiong et autres

Abstract Recent genome-wide screens have identified ERK as a central signaling hub in KRAS-mutant tumors and a key driver of resistance to KRAS-targeted therapies. However, prior clinical development of ERK1/2 inhibitors has been hindered by narrow therapeutic windows and on-target toxicity. Consequently, …

cn, au, us (code pays fourni par la source)

Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883

Michael Grant, Barbara Cipriani, Alastair Corbin, David J. Miller et autres

Figure/Legend [...]

gb, au, us, es (code pays fourni par la source)

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Gregory Michael Cote, Mason Aberoumand, E. Choy, Lucille T. Sebastian et autres

PURPOSE: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis …

us, au, jp (code pays fourni par la source)

Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma

Michael Grant, Barbara Cipriani, Alastair Corbin, David J. Miller et autres

Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy accounting for 3% of adult cancers globally. Despite advances in immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF)-targeted therapies, durable disease control remains elusive for many patients. Increasing evidence implicates the …

gb, au, us, es (code pays fourni par la source)

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

James Larkin, Michele Del Vecchio, Mario Mandalà, Helen J Gogas et autres

DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

Prognostic Value of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lactate Dehydrogenase Level in Melanoma Patients Treated with Immune Checkpoint Inhibitors

Wynne Wijaya, Muhammad Adnan Khattak, Afaf Abed, Tarek M. Meniawy et autres

Introduction Metastatic melanoma carries a poor prognosis. Immune checkpoint inhibitors (ICIs) have improved outcomes, but responses remain variable, highlighting the need for simple prognostic biomarkers. Inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) reflect tumour burden …

gb, au (code pays fourni par la source)

572 Preliminary safety, pharmacokinetic and pharmacodynamic analysis from the ongoing RAISIC-1 (relief of acidic immune suppression in cancer): phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256

Ganessan Kichenadasse, Joe Wei, Bo Gao, Andrew James Weickhardt et autres

Background PTT-4256 is a first-in-class, potent, orally-bioavailable allosteric, small molecule inhibitor of the pH-sensing G protein-coupled receptor (GPCR), GPR65, expressed on tumour-infiltrating immune cells. In the tumour micro-environment (TME), which has an acidic (i.e. lower than surrounding normal tissue) pH, GPR65 is …

au, gb (code pays fourni par la source)

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

Timothy Anthony Yap, David J. Kwiatkowski, Ibiayi Dagogo‐Jack, Michael David Offin et autres

us, au, in, pt (code pays fourni par la source)

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Paolo A. Ascierto, Michele Del Vecchio, Barbara Merelli, Helen J Gogas et autres

BACKGROUND: In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival. METHODS: We randomly assigned patients in a …

it, gr, es, fr, us, ro, ca, cz, au, gb (code pays fourni par la source)

PYNNACLE phase II trial assessing rezatapopt (PC14586), a selective p53 reactivator, in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation

Ecaterina E Ileana Dumbrava, Giuseppe Curigliano, Anthony B. El-Khoueiry, Alastair Greystoke et autres

us, it, gb, kr, fr, au, es, sg (code pays fourni par la source)

973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations

Subotheni Thavaneswaran, David Espinoza, F.P. Lin, S. Chinchen et autres

au, us (code pays fourni par la source)

PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Alison M. Schram, Jean‐Sébastien Frenel, Melissa Lynne Johnson, Antoîne Italiano et autres

TPS11581 Background: TP53, encoding p53 protein, is one of the most frequently mutated genes across all cancers, with TP53 mutations found in ~59% of all solid tumors. TP53 mutations result in the loss of p53 tumor suppressor functions leading to tumor development …

us, fr, au, gb, es, sg (code pays fourni par la source)